Urogen Pharma Ltd URGN:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 4:00 PM EDT
13.21UNCH (UNCH)
Volume
6,112
Close
13.21quote price arrow down-0.57 (-4.14%)
Volume
201,297
52 week range
8.69 - 24.13
Loading...
  • Open13.72
  • Day High13.72
  • Day Low13.19
  • Prev Close13.78
  • 52 Week High24.13
  • 52 Week High Date08/15/23
  • 52 Week Low8.69
  • 52 Week Low Date07/26/23

Key Stats

  • Market Cap477.279M
  • Shares Out36.13M
  • 10 Day Average Volume0.36M
  • Dividend-
  • Dividend Yield-
  • Beta1.10
  • YTD % Change-11.93

KEY STATS

  • Open13.72
  • Day High13.72
  • Day Low13.19
  • Prev Close13.78
  • 52 Week High24.13
  • 52 Week High Date08/15/23
  • 52 Week Low8.69
  • 52 Week Low Date07/26/23
  • Market Cap477.279M
  • Shares Out36.13M
  • 10 Day Average Volume0.36M
  • Dividend-
  • Dividend Yield-
  • Beta1.10
  • YTD % Change-11.93

RATIOS/PROFITABILITY

  • EPS (TTM)-3.39
  • P/E (TTM)-3.90
  • Fwd P/E (NTM)-3.77
  • EBITDA (TTM)-68.499M
  • ROE (TTM)-1,481.26%
  • Revenue (TTM)84.302M
  • Gross Margin (TTM)89.53%
  • Net Margin (TTM)-123.74%
  • Debt To Equity (MRQ)-243.16%

EVENTS

  • Earnings Date08/08/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Urogen Pharma Ltd

 

Profile

MORE
UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or...
Arie Belldegrun M.D.
Independent Chairman of the Board
Elizabeth Barrett
President, Chief Executive Officer, Director
Dong Kim
Chief Financial Officer
Address
9 Ha'ta'asiya St
Ra'anana
4365007
Israel

Top Peers

SYMBOLLASTCHG%CHG
YMAB
Y-mAbs Therapeutics Inc
11.85-0.33-2.71%
EDIT
Editas Medicine Inc
5.89-0.11-1.83%
ALEC
Alector Inc
5.49-0.16-2.83%
TBPH
Theravance Biopharma Inc
9.60-0.25-2.54%
ADCT
ADC Therapeutics SA
4.09-0.04-0.97%